Talimogene laherparepvec: First in class oncolytic virotherapy
Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at distant, uninjected sites. Talimogene laherpar...
Saved in:
| Published in | Human vaccines & immunotherapeutics Vol. 14; no. 4; pp. 839 - 846 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Taylor & Francis
03.04.2018
Taylor & Francis Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at distant, uninjected sites. Talimogene laherparepvec (TVEC) is a type I herpes simplex virus genetically modified to preferentially replicate in tumor cells, enhance antigen loading of MHC class I molecules and express granulocyte-macrophage colony-stimulating factor to increase tumor-antigen presentation by dendritic cells. It is presently the only oncolytic virus approved by the FDA with an indication for advanced melanoma based upon improved durable response rate in a randomized, phase III trial. Clinical trials are underway in melanoma investigating TVEC as neoadjuvant monotherapy and in combination with checkpoint inhibitors for unresectable disease as well as in an array of other malignancies. It is appropriate to review TVEC's biology mechanism of action, clinical indication and future directions as a prototype of the burgeoning class of oncolytic viruses. |
|---|---|
| AbstractList | Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at distant, uninjected sites. Talimogene laherparepvec (TVEC) is a type I herpes simplex virus genetically modified to preferentially replicate in tumor cells, enhance antigen loading of MHC class I molecules and express granulocyte-macrophage colony-stimulating factor to increase tumor-antigen presentation by dendritic cells. It is presently the only oncolytic virus approved by the FDA with an indication for advanced melanoma based upon improved durable response rate in a randomized, phase III trial. Clinical trials are underway in melanoma investigating TVEC as neoadjuvant monotherapy and in combination with checkpoint inhibitors for unresectable disease as well as in an array of other malignancies. It is appropriate to review TVEC's biology mechanism of action, clinical indication and future directions as a prototype of the burgeoning class of oncolytic viruses.Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at distant, uninjected sites. Talimogene laherparepvec (TVEC) is a type I herpes simplex virus genetically modified to preferentially replicate in tumor cells, enhance antigen loading of MHC class I molecules and express granulocyte-macrophage colony-stimulating factor to increase tumor-antigen presentation by dendritic cells. It is presently the only oncolytic virus approved by the FDA with an indication for advanced melanoma based upon improved durable response rate in a randomized, phase III trial. Clinical trials are underway in melanoma investigating TVEC as neoadjuvant monotherapy and in combination with checkpoint inhibitors for unresectable disease as well as in an array of other malignancies. It is appropriate to review TVEC's biology mechanism of action, clinical indication and future directions as a prototype of the burgeoning class of oncolytic viruses. Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at distant, uninjected sites. Talimogene laherparepvec (TVEC) is a type I herpes simplex virus genetically modified to preferentially replicate in tumor cells, enhance antigen loading of MHC class I molecules and express granulocyte-macrophage colony-stimulating factor to increase tumor-antigen presentation by dendritic cells. It is presently the only oncolytic virus approved by the FDA with an indication for advanced melanoma based upon improved durable response rate in a randomized, phase III trial. Clinical trials are underway in melanoma investigating TVEC as neoadjuvant monotherapy and in combination with checkpoint inhibitors for unresectable disease as well as in an array of other malignancies. It is appropriate to review TVEC's biology mechanism of action, clinical indication and future directions as a prototype of the burgeoning class of oncolytic viruses. |
| Author | Norwood, Timothy Graham Westbrook, Brian Conry, Robert M. McKee, Svetlana |
| Author_xml | – sequence: 1 givenname: Robert M. surname: Conry fullname: Conry, Robert M. organization: Medicine/Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA – sequence: 2 givenname: Brian surname: Westbrook fullname: Westbrook, Brian organization: Medicine, University of Alabama at Birmingham, Birmingham, AL, USA – sequence: 3 givenname: Svetlana surname: McKee fullname: McKee, Svetlana organization: Medicine/Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA – sequence: 4 givenname: Timothy Graham surname: Norwood fullname: Norwood, Timothy Graham organization: Medicine, University of Alabama at Birmingham, Birmingham, AL, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29420123$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU9r3DAQxUVJaf40H6HFx152K40ly24hUEKTBgK9JJCbGMvjjYLWciXvwn77arubpckl0kFi9N5vBr1TdjSEgRj7JPhc8Jp_BVFJpYSaAxd6LqSAuqnesZNtfaaUfDg63IU6ZucpPfG8NAdZVR_YMTQyO6E8YRd36N0yLGigwuMjxREjjWuy34orF9NUuKGwHlMqwmCD30zOFmsXw5SlOG4-svc9-kTn-_OM3V_9vLv8Nbv9fX1z-eN2ZqXW08w2oOoO-koAdSWAFrLSErFUtpVStZ3FDsCC4E3Lywq1JkBuQbe6F3mXZ-xmx-0CPpkxuiXGjQnozL9CiAuDMc_myQgNrcUGZV31md03NSDVrbZIquGKZ9bFjjWu2iV1loYpon8BffkyuEezCGuj6qYEITLgyx4Qw58VpcksXbLkPQ4UVskA5yL_da3rLP38f69Dk-cAskDtBDaGlCL1B4ngZpu1ec7abLM2-6yz7_srn3UTTi5sR3b-Dfdfd4atmA |
| CitedBy_id | crossref_primary_10_1097_MOO_0000000000000651 crossref_primary_10_3390_biomedicines13010098 crossref_primary_10_1158_2767_9764_CRC_22_0365 crossref_primary_10_1002_rmv_2268 crossref_primary_10_1016_j_ymthe_2024_12_054 crossref_primary_10_1038_s41392_024_02029_2 crossref_primary_10_3390_cancers12061699 crossref_primary_10_3390_vaccines9060614 crossref_primary_10_3390_v13071294 crossref_primary_10_1080_17460441_2021_1942834 crossref_primary_10_1016_j_biopha_2021_112512 crossref_primary_10_3390_molecules25184096 crossref_primary_10_3389_fimmu_2020_01180 crossref_primary_10_1007_s13555_021_00583_z crossref_primary_10_3389_fimmu_2019_01848 crossref_primary_10_1016_j_cytogfr_2020_07_002 crossref_primary_10_1158_1078_0432_CCR_19_0405 crossref_primary_10_1016_j_ymthe_2020_03_014 crossref_primary_10_1016_j_omtm_2021_12_002 crossref_primary_10_1186_s12879_021_06995_8 crossref_primary_10_3389_fimmu_2021_679117 crossref_primary_10_1016_j_yao_2022_02_004 crossref_primary_10_1016_j_addr_2019_06_005 crossref_primary_10_1007_s11912_021_01130_x crossref_primary_10_3390_ijms21197073 crossref_primary_10_1155_2024_8820105 crossref_primary_10_3389_fmolb_2022_965730 crossref_primary_10_1016_j_omto_2019_03_010 crossref_primary_10_1016_j_omto_2023_07_006 crossref_primary_10_1097_CMR_0000000000000824 crossref_primary_10_1016_j_lfs_2020_117550 crossref_primary_10_3390_cancers15092453 crossref_primary_10_3389_fgene_2021_750675 crossref_primary_10_1016_j_ejphar_2018_08_042 crossref_primary_10_3171_2020_12_FOCUS20855 crossref_primary_10_3389_fonc_2022_888100 crossref_primary_10_3390_vaccines12070721 crossref_primary_10_1007_s11523_020_00767_1 crossref_primary_10_1038_s42003_021_01914_8 crossref_primary_10_1089_hum_2020_278 crossref_primary_10_3390_v16050775 crossref_primary_10_3390_v11090856 crossref_primary_10_2217_imt_2020_0344 crossref_primary_10_1172_JCI149310 crossref_primary_10_1016_j_trsl_2021_04_008 crossref_primary_10_3390_cancers13051044 crossref_primary_10_3390_ijms21155337 crossref_primary_10_3390_ijms21218310 crossref_primary_10_3390_curroncol28010019 crossref_primary_10_1016_j_intimp_2022_108580 crossref_primary_10_1016_j_biotechadv_2019_107502 crossref_primary_10_1146_annurev_virology_012220_023606 crossref_primary_10_18527_2500_2236_2022_9_1_91_112_RU crossref_primary_10_1007_s13311_022_01256_1 crossref_primary_10_1016_j_biopha_2020_110932 crossref_primary_10_1177_10781552241312920 crossref_primary_10_1016_j_wneu_2019_05_205 crossref_primary_10_3390_cancers12123827 crossref_primary_10_3390_cancers15153901 crossref_primary_10_1038_s41573_021_00175_8 crossref_primary_10_3390_nano9010105 crossref_primary_10_3389_fbioe_2021_628137 crossref_primary_10_3389_fmicb_2020_491001 crossref_primary_10_1016_j_addr_2021_113896 crossref_primary_10_1016_j_cytogfr_2020_06_005 crossref_primary_10_1016_j_semcancer_2022_12_003 crossref_primary_10_1007_s11010_023_04669_4 crossref_primary_10_1016_j_omto_2022_05_013 crossref_primary_10_1016_j_xphs_2020_09_057 crossref_primary_10_3390_cancers11101532 crossref_primary_10_3390_cancers16234002 crossref_primary_10_1002_adma_202301770 crossref_primary_10_1002_cac2_12597 crossref_primary_10_1200_OA_24_00049 crossref_primary_10_3389_fmolb_2022_831091 crossref_primary_10_1002_wnan_1872 crossref_primary_10_3390_ijms252111466 crossref_primary_10_3390_v11060562 crossref_primary_10_1245_s10434_021_10910_5 crossref_primary_10_3390_biomedicines10010173 crossref_primary_10_1186_s12929_019_0542_9 crossref_primary_10_1155_2020_4956946 crossref_primary_10_2147_OV_S186337 crossref_primary_10_1016_j_trsl_2020_04_008 crossref_primary_10_4103_JIPO_JIPO_1_20 crossref_primary_10_15616_BSL_2018_24_3_157 crossref_primary_10_3389_fmolb_2024_1403021 crossref_primary_10_3390_ijms24119255 crossref_primary_10_1155_2024_2167176 crossref_primary_10_1158_1078_0432_CCR_21_1248 crossref_primary_10_3389_fonc_2019_00425 crossref_primary_10_1136_jitc_2021_003254 crossref_primary_10_1016_j_soncn_2019_08_007 crossref_primary_10_3390_ijms21207743 crossref_primary_10_1016_j_onano_2022_100107 crossref_primary_10_1002_btm2_10258 crossref_primary_10_1099_jgv_0_001752 crossref_primary_10_1016_j_prp_2022_154241 crossref_primary_10_3390_ijms21207627 crossref_primary_10_3390_ijms21207505 crossref_primary_10_1016_j_omto_2023_100729 crossref_primary_10_3389_fvets_2021_621758 crossref_primary_10_3390_ijms25020947 crossref_primary_10_1016_j_addr_2020_06_024 crossref_primary_10_1007_s12032_023_02106_6 crossref_primary_10_2174_1573394716666200211120906 crossref_primary_10_1016_j_phrs_2020_105094 crossref_primary_10_1136_jitc_2020_001580 crossref_primary_10_3389_fimmu_2020_01624 crossref_primary_10_1007_s13577_022_00821_2 crossref_primary_10_1002_adma_202103790 crossref_primary_10_1016_j_lfs_2024_122652 crossref_primary_10_1002_jmv_70067 crossref_primary_10_3390_vaccines9060668 crossref_primary_10_1016_j_biopha_2022_113324 crossref_primary_10_1002_adfm_201908743 crossref_primary_10_3390_cancers16101800 crossref_primary_10_2217_mmt_2020_0011 crossref_primary_10_1007_s11095_022_03434_4 crossref_primary_10_1016_j_gpb_2021_02_004 crossref_primary_10_3389_fimmu_2020_01075 crossref_primary_10_1007_s12325_021_01916_2 crossref_primary_10_1016_j_omto_2023_01_003 crossref_primary_10_1016_j_hoc_2018_12_001 crossref_primary_10_1038_s41598_020_61275_w crossref_primary_10_3390_cancers13225687 crossref_primary_10_1016_j_memsci_2020_118804 crossref_primary_10_1186_s12967_024_05650_5 crossref_primary_10_1007_s11864_020_00739_7 crossref_primary_10_3390_ijms221910629 crossref_primary_10_3390_vaccines10050740 crossref_primary_10_1016_j_matbio_2023_04_002 crossref_primary_10_1016_j_drudis_2022_02_009 crossref_primary_10_1136_jitc_2021_003119 crossref_primary_10_1016_j_addr_2022_114421 crossref_primary_10_1017_ice_2018_358 crossref_primary_10_1021_acs_chemrev_1c00877 crossref_primary_10_1002_ccr3_9632 crossref_primary_10_1007_s11684_020_0750_4 crossref_primary_10_1016_j_tranon_2021_101166 crossref_primary_10_3389_fmolb_2021_623475 crossref_primary_10_1002_mabi_202300275 crossref_primary_10_1177_00031348211023434 crossref_primary_10_1016_j_mbs_2021_108556 crossref_primary_10_3389_fgeed_2021_618346 crossref_primary_10_1002_smll_202206948 crossref_primary_10_1007_s11912_020_00944_5 crossref_primary_10_3390_v12111324 crossref_primary_10_1007_s12015_021_10207_w crossref_primary_10_1136_jim_2021_002205 crossref_primary_10_3390_biomedicines11082100 crossref_primary_10_3390_ijms21031106 crossref_primary_10_7759_cureus_70700 crossref_primary_10_1038_s43018_022_00448_0 crossref_primary_10_1126_science_abc4552 crossref_primary_10_3390_biomedicines8030060 crossref_primary_10_3390_biomedicines9020138 crossref_primary_10_1016_j_ebiom_2019_08_011 crossref_primary_10_1002_ggn2_202300201 crossref_primary_10_1136_jitc_2021_004307 crossref_primary_10_1038_s41598_021_01473_2 crossref_primary_10_1186_s12935_022_02774_w crossref_primary_10_4103_jcrt_JCRT_1241_20 crossref_primary_10_1186_s12967_023_04110_w crossref_primary_10_1016_j_ctarc_2021_100473 crossref_primary_10_1016_j_omto_2021_06_008 crossref_primary_10_3389_fmolb_2022_777775 crossref_primary_10_3390_cancers12051104 crossref_primary_10_3390_cancers17050821 crossref_primary_10_1177_17588359221083052 crossref_primary_10_1186_s41231_023_00144_w crossref_primary_10_1159_000530851 crossref_primary_10_1159_000518106 crossref_primary_10_1089_dna_2022_0375 crossref_primary_10_1038_s41581_020_0316_3 crossref_primary_10_3390_ijms23094865 crossref_primary_10_1016_j_ygyno_2021_01_018 crossref_primary_10_1007_s10555_022_10022_w crossref_primary_10_1016_j_ejca_2022_05_024 crossref_primary_10_1021_acssynbio_1c00266 crossref_primary_10_3390_pharmaceutics13122192 crossref_primary_10_37748_2686_9039_2021_2_3_3 crossref_primary_10_1016_j_bcp_2020_113986 crossref_primary_10_1080_14712598_2020_1693541 crossref_primary_10_1007_s10585_021_10100_3 crossref_primary_10_3390_v13010017 crossref_primary_10_1016_j_ejphar_2024_177143 crossref_primary_10_1155_2020_8680692 crossref_primary_10_1016_j_molmed_2023_01_006 crossref_primary_10_1038_s41573_020_0064_x crossref_primary_10_34104_ajpab_024_01690175 crossref_primary_10_3390_biomedicines7030066 crossref_primary_10_3390_jcm9030675 crossref_primary_10_2217_fon_2022_0440 crossref_primary_10_1016_j_trecan_2022_10_003 crossref_primary_10_18527_2500_2236_2022_9_1_91_112 crossref_primary_10_3390_cells10061541 crossref_primary_10_1002_psp4_12898 crossref_primary_10_3390_jcm9113529 crossref_primary_10_1016_j_ctarc_2021_100323 crossref_primary_10_1111_iep_12478 crossref_primary_10_3390_cancers12113327 crossref_primary_10_1186_s12935_021_02024_5 crossref_primary_10_1038_s41523_022_00486_y crossref_primary_10_1016_j_omto_2020_07_003 crossref_primary_10_1007_s11912_023_01422_4 crossref_primary_10_1016_j_ejca_2021_08_004 crossref_primary_10_1038_s41417_019_0112_z crossref_primary_10_1136_jitc_2023_008460 crossref_primary_10_3390_nano11113018 crossref_primary_10_3390_biomedicines12071577 crossref_primary_10_1007_s40588_019_00121_8 crossref_primary_10_1021_acs_molpharmaceut_2c00775 crossref_primary_10_1136_jitc_2021_002454 crossref_primary_10_3390_cells9020400 crossref_primary_10_1158_1078_0432_CCR_20_0245 crossref_primary_10_1016_j_ejphar_2020_172991 crossref_primary_10_1016_j_omtm_2022_06_007 crossref_primary_10_1007_s00262_021_03084_2 crossref_primary_10_1007_s40883_023_00295_0 crossref_primary_10_1136_jitc_2020_001624 crossref_primary_10_1016_j_jdcr_2019_06_034 crossref_primary_10_3390_v14030525 |
| Cites_doi | 10.18632/oncotarget.18309 10.2217/imt.15.35 10.1038/mt.2014.160 10.1038/sj.onc.1203127 10.1245/s10434-009-0809-6 10.1016/S1470-2045(01)00618-0 10.1111/cup.13048 10.1128/JVI.80.3.1110-1120.2006 10.1002/hed.24522 10.1126/science.1851332 10.1186/1743-422X-11-83 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O 10.1126/scitranslmed.3008095 10.1073/pnas.94.3.843 10.1038/sj.gt.3301885 10.1158/1078-0432.CCR-15-2667 10.1158/1078-0432.CCR-10-0196 10.1186/s40425-015-0078-9 10.1016/j.jdcr.2017.02.003 10.1038/35087061 10.1111/pcmr.12419 10.2147/OTT.S115245 10.1186/1479-5876-11-20 10.1200/JCO.2009.24.3675 10.1097/CJI.0b013e318272569b 10.1128/JVI.72.3.2560-2563.1998 10.1200/JCO.2006.08.5829 10.1158/1078-0432.CCR-09-1624 10.2174/156652321306140103224550 10.1186/2051-1426-2-11 10.1007/s40257-016-0238-9 10.1016/j.ymthe.2017.03.026 10.1016/j.cell.2017.08.027 10.1001/jama.2014.13943 10.1200/jco.2014.32.15_suppl.9029 10.1158/1078-0432.CCR-06-0759 10.1056/NEJMoa1003466 10.1016/j.jdcr.2017.02.011 10.1200/JCO.2017.35.15_suppl.9509 10.1002/ijc.25088 |
| ContentType | Journal Article |
| Copyright | 2018 The Author(s). Published with license by Taylor & Francis 2018 The Author(s) |
| Copyright_xml | – notice: 2018 The Author(s). Published with license by Taylor & Francis 2018 The Author(s) |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1080/21645515.2017.1412896 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | R. M. CONRY ET AL |
| EISSN | 2164-554X |
| EndPage | 846 |
| ExternalDocumentID | oai_doaj_org_article_172bca9a486f445f982ae8b7cae59050 PMC5893211 29420123 10_1080_21645515_2017_1412896 |
| Genre | Journal Article Review |
| GroupedDBID | --- 00X 0YH 30N 4.4 53G AALUX AAYXX ABEIZ ABUPF ACGFS ADBBV ADCVX AECIN AENEX AGYJP AIJEM ALMA_UNASSIGNED_HOLDINGS ALQZU AOIJS ARJSQ BABNJ BAWUL BLEHA BOHLJ CCCUG CITATION DGEBU DIK EBS EJD H13 HYE IPNFZ KYCEM M4Z O9- RIG RPM TDBHL TFL TFW TTHFI ACENM AEXWM CGR CUY CVF ECM EIF NPM OK1 7X8 5PM GROUPED_DOAJ |
| ID | FETCH-LOGICAL-c477t-c9258d2f612ed322714674aa35cb445bdcad22c2109b036a77e2a0c27b7f1f1f3 |
| IEDL.DBID | DOA |
| ISSN | 2164-5515 2164-554X |
| IngestDate | Wed Aug 27 01:31:48 EDT 2025 Thu Aug 21 14:04:02 EDT 2025 Thu Jul 10 22:44:56 EDT 2025 Thu Jan 02 23:03:14 EST 2025 Thu Apr 24 22:59:56 EDT 2025 Tue Jul 01 02:46:05 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Talimogene laherparepvec herpes simplex viral type I granulomatous dermatitis oncolytic virus granulocyte-macrophage colony-stimulating factor melanoma immune checkpoint blockade |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c477t-c9258d2f612ed322714674aa35cb445bdcad22c2109b036a77e2a0c27b7f1f1f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://doaj.org/article/172bca9a486f445f982ae8b7cae59050 |
| PMID | 29420123 |
| PQID | 2001070878 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_172bca9a486f445f982ae8b7cae59050 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5893211 proquest_miscellaneous_2001070878 pubmed_primary_29420123 crossref_primary_10_1080_21645515_2017_1412896 crossref_citationtrail_10_1080_21645515_2017_1412896 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-04-03 |
| PublicationDateYYYYMMDD | 2018-04-03 |
| PublicationDate_xml | – month: 04 year: 2018 text: 2018-04-03 day: 03 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Human vaccines & immunotherapeutics |
| PublicationTitleAlternate | Hum Vaccin Immunother |
| PublicationYear | 2018 |
| Publisher | Taylor & Francis Taylor & Francis Group |
| Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
| References | cit0011 cit0033 cit0012 cit0034 Chang KJ (cit0046) 2012; 30 Kaufman HL (cit0027) 2016; 6 cit0019 cit0017 cit0039 cit0018 cit0037 cit0016 cit0038 cit0013 cit0035 cit0014 Coffin RS (cit0015) 1996; 3 cit0036 cit0044 cit0001 cit0023 cit0045 cit0020 Chesney J (cit0041) 2017; 35 cit0042 cit0021 Tomazin R (cit0010) 1998; 72 Zhang KX (cit0008) 2010; 127 Leung ACF (cit0031); 2017 Puzanov I (cit0040) 2014; 32 Andtbacka RHI (cit0022) 2015; 28 Kaufman H (cit0028) 2015 Long G (cit0030); 2017 cit0009 cit0006 cit0007 cit0004 cit0026 cit0048 cit0005 Robert C (cit0029); 2017 Robert C (cit0043) 2017; 73 cit0049 cit0002 cit0024 cit0003 cit0025 cit0047 |
| References_xml | – ident: cit0001 doi: 10.18632/oncotarget.18309 – year: 2015 ident: cit0028 publication-title: ASCO – ident: cit0024 doi: 10.2217/imt.15.35 – ident: cit0038 doi: 10.1038/mt.2014.160 – ident: cit0004 doi: 10.1038/sj.onc.1203127 – volume: 2017 issue: 35 ident: cit0031 publication-title: J Clin Oncol – ident: cit0014 doi: 10.1245/s10434-009-0809-6 – ident: cit0017 doi: 10.1016/S1470-2045(01)00618-0 – ident: cit0035 doi: 10.1111/cup.13048 – ident: cit0006 doi: 10.1128/JVI.80.3.1110-1120.2006 – ident: cit0025 doi: 10.1002/hed.24522 – ident: cit0048 doi: 10.1126/science.1851332 – ident: cit0033 doi: 10.1186/1743-422X-11-83 – ident: cit0007 doi: 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O – ident: cit0018 doi: 10.1126/scitranslmed.3008095 – volume: 6 start-page: 46 year: 2016 ident: cit0027 publication-title: J Immuno Therapy Cancer – ident: cit0009 doi: 10.1073/pnas.94.3.843 – volume: 30 year: 2012 ident: cit0046 publication-title: J Clin Oncol – ident: cit0012 doi: 10.1038/sj.gt.3301885 – ident: cit0003 doi: 10.1158/1078-0432.CCR-15-2667 – ident: cit0045 doi: 10.1158/1078-0432.CCR-10-0196 – ident: cit0042 doi: 10.1186/s40425-015-0078-9 – volume: 73 start-page: 193 year: 2017 ident: cit0043 publication-title: Am J Health Syst Pharm – ident: cit0047 doi: 10.1016/j.jdcr.2017.02.003 – ident: cit0005 doi: 10.1038/35087061 – volume: 28 start-page: 753 issue: 6 year: 2015 ident: cit0022 publication-title: Cell Melanoma Res doi: 10.1111/pcmr.12419 – ident: cit0023 doi: 10.2147/OTT.S115245 – ident: cit0049 doi: 10.1186/1479-5876-11-20 – ident: cit0019 doi: 10.1200/JCO.2009.24.3675 – volume: 2017 ident: cit0029 publication-title: J Clin Oncol – ident: cit0037 doi: 10.1097/CJI.0b013e318272569b – volume: 72 start-page: 2560 year: 1998 ident: cit0010 publication-title: J Virol doi: 10.1128/JVI.72.3.2560-2563.1998 – ident: cit0036 doi: 10.1200/JCO.2006.08.5829 – ident: cit0021 doi: 10.1158/1078-0432.CCR-09-1624 – ident: cit0034 doi: 10.2174/156652321306140103224550 – ident: cit0011 doi: 10.1186/2051-1426-2-11 – volume: 2017 ident: cit0030 publication-title: J Clin Oncol – ident: cit0013 doi: 10.1007/s40257-016-0238-9 – ident: cit0002 doi: 10.1016/j.ymthe.2017.03.026 – volume: 3 start-page: 886 issue: 10 year: 1996 ident: cit0015 publication-title: Gene Ther – ident: cit0044 doi: 10.1016/j.cell.2017.08.027 – ident: cit0039 doi: 10.1001/jama.2014.13943 – volume: 32 start-page: 9029 year: 2014 ident: cit0040 publication-title: J Clin Oncol doi: 10.1200/jco.2014.32.15_suppl.9029 – ident: cit0016 doi: 10.1158/1078-0432.CCR-06-0759 – ident: cit0020 doi: 10.1056/NEJMoa1003466 – ident: cit0026 doi: 10.1016/j.jdcr.2017.02.011 – volume: 35 start-page: JCO2017737379 year: 2017 ident: cit0041 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.35.15_suppl.9509 – volume: 127 start-page: 830 year: 2010 ident: cit0008 publication-title: Int J Cancer doi: 10.1002/ijc.25088 |
| SSID | ssj0000702466 |
| Score | 2.563815 |
| SecondaryResourceType | review_article |
| Snippet | Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 839 |
| SubjectTerms | Animals Antigens, Neoplasm - immunology Dendritic Cells - immunology granulocyte-macrophage colony-stimulating factor granulomatous dermatitis herpes simplex viral type i Herpesvirus 1, Human - immunology Humans immune checkpoint blockade Immunotherapy - methods melanoma Oncolytic Virotherapy - methods oncolytic virus Oncolytic Viruses - immunology Product Review Randomized Controlled Trials as Topic talimogene laherparepvec |
| Title | Talimogene laherparepvec: First in class oncolytic virotherapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29420123 https://www.proquest.com/docview/2001070878 https://pubmed.ncbi.nlm.nih.gov/PMC5893211 https://doaj.org/article/172bca9a486f445f982ae8b7cae59050 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dS8MwED90IPgifls_RgVf67o0WVIfBBXHENzTBnsrSZriQNuhm7D_3ru2G5sIe5G-pU173F1yv2vuA-Am6iDsNaodqFSEAUcTGihBf8RMFGbWOp6VuVWv_U5vyF9GYrTS6otiwqrywBXjWmhgjdWx5qqD00QWK6adMtJqJ-Kw8tbR5q04U-UeLNH2lAeVDP2BAGGBWKTvqLBFYzREkV0S9wrco6lo_4phKuv3_wU6f8dOrhij7j7s1SjSf6ioP4Atlx_CTtVXcn4E9wNE1x8F6obz3zVKhcLMJ9_O3vndMcI9f5z7lmCzX-SoCHN8i0_5blUy1vwYht3nwVMvqBslBJZLOQ1szIRKWYZoxaW4QiVtf1zrSFiDPDOp1SljFr272KDF0lI6pkPLpJFZG6_oBBp5kbsz8E2ohcqQPZHUaLesFsYgZNDKsDQyMfeAL7iU2LqKODWzeE_adbHRBXMTYm5SM9eD2-W0SVVGY9OERxLB8mGqgl0OoG4ktW4km3TDg-uFABNcNXQUonNXzL6o-Sb6vaGSyoPTSqDLT7GYM0KaHsg1Ua_Rsn4nH7-VlbkFoj_0qM__g_gL2EUyVBklFF1CY_o5c1cIgKamCdtR2G-WGv8DeEL9PA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Talimogene+laherparepvec%3A+First+in+class+oncolytic+virotherapy&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Conry%2C+Robert+M.&rft.au=Westbrook%2C+Brian&rft.au=McKee%2C+Svetlana&rft.au=Norwood%2C+Timothy+Graham&rft.date=2018-04-03&rft.pub=Taylor+%26+Francis&rft.issn=2164-5515&rft.eissn=2164-554X&rft.volume=14&rft.issue=4&rft.spage=839&rft.epage=846&rft_id=info:doi/10.1080%2F21645515.2017.1412896&rft_id=info%3Apmid%2F29420123&rft.externalDocID=PMC5893211 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon |